PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Oxford Biodynamics launches prostate screening test

EpiSwitch is designed for men with prostate cancer risk in the UK and is 94% accurate.

Oxford BioDynamics – a company developing precision medicine tests – has announced that its EpiSwitch Prostate Screening (PSE) blood test will be available to UK patients.

The existing PSA test is 55% accurate and is considered an unreliable test by many doctors, including those in the NHS.

The new PSE test has been designed to run alongside the standard PSA test and combines the PSA score with five proprietary epigenetic biomarkers to predict – with 94% accuracy – the presence (or absence) of prostate cancer.

The PSE test has emerged after nearly a decade-long collaboration between OBD, Imperial College London, University of East Anglia, Imperial College NHS Trust and leading prostate cancer experts across the UK. The development was also part of the wider PROSTAGRAM screening pilot.

Mathias Winkler, Consultant Urologist and Surgeon at Charing Cross Hospital and Imperial College London was optimistic about the launch. “PSE is a diagnostic prostate cancer test with unprecedented accuracy. Nine of 10 cancers are found compared to three of ten with PSA alone. Likewise, false-positive results are reduced avoiding unnecessary anxiety and expense.”

He added: “This is clearly highly desirable for men who are health-conscious or at risk of prostate cancer. We are delighted to be part of the team evaluating and refining the test for use in particular risk groups and prospectively validating in a larger patient cohort compared to the current standard of care.”

Across the UK, around 120,000 patients undergo a prostate biopsy every year, while only about a quarter of those who have a prostate biopsy due to an elevated PSA level are found to have prostate cancer.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026